IsoRay touts another ‘ 100% ’ study

IsoRay (NYSE:ISR) today released data from a study of its Cesium-131 brachytherapy for treating patients with large brain metastases, touting a 100% freedom from local progression. Results from the study were published in the International Journal of Radiation Oncology, Biology, Physics, the Richland, Wash.-based company said. In the study, researchers assessed the impact of low-dose rate Cesium-131 brachytherapy on local control and radionecrosis in 42 patients treated for a total of 46 large brain metastases. Patients in the trial underwent surgical resection with intra-operative palcement of standard Cesium-131 seeds as permanent volume implants in the resection cavity, the company said. Results from the trial indicated a 100% freedom from local progression rate, meaning brain metastases did not re-grow, and a 0% rate of radionecrosis. Study authors concluded that the Cesium-131 brachytherapy was “safe and effective adjuvant therapy for large brain metastases requiring neurosurgical intervention,” the company said. “Evidence of Cesium-131’s efficacy in treating brain cancer continues to increase as supported by this important study. The work of Drs. Wernicke and Schwartz is truly pioneering and provides hope that we can continue to improve the available treatment for those afflicted with brain metastases. Treatment of brain metastases is a large unmet need and we’re gratified that our Cesium-131 product has promise to be effective for the ma...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Oncology IsoRay Source Type: news